Previous 10 | Next 10 |
HOUSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced that the Company will host a con...
HOUSTON, March 08, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the closing of its previously an...
Salarius Pharmaceuticals (SLRX) trades 12.4% down premarket after pricing its underwritten public offering of 14.6M shares at $1.3685/share.Underwriters granted 45-day option to purchase up to 2.1M shares.Gross proceeds expected to be ~$20M.Offer close expected on or ...
HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the pricing of an underwritten p...
Salarius Pharmaceuticals (SLRX) trades 5.6% down after hours on commencing an underwritten public offering of shares.Offer size, terms not yet disclosed. For further details see: Salarius Pharmaceuticals readies stock offering
ASLAN Pharmaceuticals Limited (ASLN) +71% as ASLAN004 shows positive effect in atopic dermatitis.Apollo Endosurgery (APEN) +47% after receiving a Breakthrough Device Designation from the USFDA for the Orbera® Intragastric Balloon.electroCore (ECOR) +39% on exclusive distri...
Gainers: Sunesis Pharmaceuticals (SNSS) +38%, Owens & Minor (OMI) +32%, Salarius Pharmaceuticals (SLRX) +20%, Poseida Therapeutics (PSTX) +20%, PRA Health Sciences (PRAH) +19%.Losers: Rafael (RFL) -12%, Constellation Pharmaceuticals (CNST)...
R. R. Donnelley & Sons Company (RRD) +46% on Q4 results.Sypris Solutions (SYPR) +62%.Salarius Pharmaceuticals (SLRX) +21% after initiating expansion stage of phase 1/2 clinical trial of Seclidemstat.Arlo Technologies (ARLO) +26% on Q4 results.Globalstar, Inc. (GSAT) +25%.Re...
Salarius Pharmaceuticals (SLRX) shares up 23% premarket after initiating the expansion stage of its ongoing Phase 1/2 clinical trial of seclidemstat in patients with relapsed and refractory (R/R) Ewing sarcoma and Ewing-related sarcomas, also known as FET-translocated sarcomas....
Relapsed and refractory Ewing sarcoma patients to receive seclidemstat in combination with chemotherapy agents as second- and third-line therapy; Protocol amendment expands and improves access to addressable patient population Ewing-related sarcoma patients to receive single-age...
News, Short Squeeze, Breakout and More Instantly...
Salarius Pharmaceuticals Inc. Company Name:
SLRX Stock Symbol:
NASDAQ Market:
Salarius Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.7% to $112.28 on volume of 455,296,152 shares Ford Motor Company (F) fell 18.4% to $11.16 on volume of 256,384,806 shares PROSHARES TRUST (SQQQ) rose 3.4% to $9.37 on volume of 246,885,889 shares Sel...
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) is one of today's top gainers. The company's shares have moved 57.21% on the day to $3.37. Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Secli...
A look at the top 10 most actives in the United States Predictive Oncology Inc. (POAI) rose 115.9% to $2.3099 on volume of 63,737,015 shares Selina Hospitality PLC (SLNA) fell 11.2% to $0.0406 on volume of 59,708,638 shares NVIDIA Corporation (NVDA) fell 1.4% to $112.695 on volume of 52,2...